Premium
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
Author(s) -
Merli Michele,
Passamonti Francesco
Publication year - 2019
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25662
Subject(s) - ibrutinib , idelalisib , medicine , ofatumumab , tolerability , oncology , context (archaeology) , dosing , randomized controlled trial , chronic lymphocytic leukemia , adverse effect , leukemia , paleontology , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom